Tsao David's Form 4 filing
BillionToOne, Inc. (BLLN) · filed Sep 8, 2026
- Accession no.
- 0002087127-26-000009
- Filed
- Sep 8, 2026, 9:55 PM ET
- Trade date
- Sep 3-8, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tsao DavidCIK 0002087127 | Director, Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Class A Common Stock | CConversionAcquired | +20,000 | $0.00F1 | $0 | 21,000 | Direct | |
| Sep 8, 2026 | Class A Common Stock | GGiftDisposed | −20,000 | $0.00 | $0 | 1,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Class A Common Stock | CConversionDisposed | −20,000 | $0.00F1 | $0 | 2,305,108 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These shares of Class B common stock were converted at a 1:1 ratio for shares of Class A common stock at the option of the holder.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.